bile duct cancer
Jazz Pharmaceuticals, MD Anderson Partner on Zanidatamab Studies in HER2-Expressing Cancers
The partners will jointly form a steering committee and fund multiple trials evaluating the HER2-targeting agent over five years.
Servier Nabs Tibsovo FDA Approval in IDH1-Mutated Myelodysplastic Syndromes
The FDA simultaneously approved Abbott Diagnostics' IDH1 test as a companion diagnostic to select IHD1-mutated relapsed or refractory MDS patients for Tibsovo.
Relay Therapeutics Seeks Tumor-Agnostic Market for FGFR2 Inhibitor Citing Medicare Pricing Pressures
Premium
Positive data from the ReFocus trial has prompted the firm to shift from a strategy for lirafugratinib in rare bile duct cancer to a broader pan-tumor approach.
GE Healthcare Licenses Sofie Biosciences' FAP-Targeting Diagnostic Radiopharmaceuticals
GE gained worldwide rights to develop and commercialize Sofie's gallium 68-labeled PET imaging agent and ex-US rights to its fluorine 18-labeled PET imaging agent.
Verismo Doses First Solid Tumor Patient With Autologous SynKIR-110 Cell Therapy
The University of Pennsylvania spinout has begun a first-in-human trial of the treatment in patients with advanced ovarian cancer, cholangiocarcinoma, and mesothelioma.